Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements), Regulations 2015 For Half Year Ended September 30,2018.
Certificate pursuant to Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for half year ended September 30,2018. Compliance Certificate For Half Year Ended September 30,2018.
Compliance Certificate pursuant to Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for half year ended September 30,2018. Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0211 Name of the Signatory :- Trivikram GudaDesignation :- Company Secretary and Compliance Officer Novartis to acquire US-based cancer drugmaker Endocyte for $2.1 billion
Novartis earlier this year announced the purchase of rare-disease drugmaker AveXis Inc. for $8.7 billion Shareholding for the Period Ended September 30, 2018
Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click here Board Meeting Intimation for Newspaper Publication
NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2018 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2018 - Newspaper Publication Board Meeting Intimation for Meeting Of Board Of Directors To Be Held On November 13,2018
NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2018 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the second quarter and half year ended September 30,2018. Novartis to cut 2,200 jobs in Switzerland to boost profitability
Novartis will cut about 2,200 jobs in Switzerland over the next four years as it consolidates production and shifts positions elsewhere to boost profitability. Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on... 